Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “Lorus Therapeutics Inc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- Lorus Therapeutics Inc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lorus Therapeutics Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lorus Therapeutics Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lorus Therapeutics Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Lorus Therapeutics Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lorus Therapeutics Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lorus Therapeutics Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opport
Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011 Reference Code: GMDHC1181CDB Publication Date: MAY 2011 Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011 GMDHC1181CDB / Published MAY 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Lorus Therapeutics Inc – Product Pipeline Review Ta b le o f Co n te n t Table of Content 2 List of Tables 4 List of Figures 5 Lorus Therapeutics Inc Snapshot 6 Lorus Therapeutics Inc Overview 6 Key Information 6 Key Facts 6 Lorus Therapeutics Inc – Research and Development Overview 7 Key Therapeutic Areas 7 Lorus Therapeutics Inc – Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products – Monotherapy 11 Pipeline Products – Combination Treatment Modalities 12 Lorus Therapeutics Inc – Pipeline Products Glance 13 Lorus Therapeutics Inc Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Lorus Therapeutics Inc–Early Stage Pipeline Products 15 Pre-Clinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Lorus Therapeutics Inc – Drug Profiles 17 GTI 2040 + Cytarabine 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LOR-2040 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LOR-2040 + Cytarabine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Virulizin 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 LOR-253 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 IL-17E 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LOR-1284 24 Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011 GMDHC1181CDB / Published MAY 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Lorus Therapeutics Inc – Product Pipeline Review Product Description 24 Mechanism of Action 24 R&D Progress 24 LOR-220 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 LOR-253 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LOR-264 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LOR-500 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Lorus Therapeutics Inc – Pipeline Analysis 29 Lorus Therapeutics Inc – Pipeline Products by Therapeutic Class 29 Lorus Therapeutics Inc - Pipeline Products By Target 31 Lorus Therapeutics Inc – Pipeline Products by Route of Administration 32 Lorus Therapeutics Inc – Pipeline Products by Molecule Type 33 Lorus Therapeutics Inc – Recent Pipeline Updates 34 Lorus Therapeutics Inc - Dormant Projects 36 Lorus Therapeutics Inc - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 Virulizin + Gemcitabine 37 Lorus Therapeutics Inc – Company Statement 38 Lorus Therapeutics Inc – Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Financial Deals Landscape 41 Lorus Therapeutics Inc, Deals Volume Summary, 2004 to YTD 2011 41 Lorus Therapeutics Inc, Deals Summary By Region, 2004 to YTD 2011 42 Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011 43 Lorus Therapeutics Inc Detailed Deal Summary 44 Equity Offering 44 Lorus Therapeutics Completes Private Placement Of $2 Million 44 Lorus Therapeutics Completes Rights Offering Of $3.63 Million 46 Lorus Therapeutics Completes Private Placement Of $1.6 Million 48 Lorus Therapeutics Completes Private Placement Of $9.22 Million 50 Debt Offering 52 Lorus Therapeutics Completes Private Placement Of Convertible Debentures For $11.96 Million 52 Lorus Therapeutics Extends Co-Operative Research Agreement With NCI 53 Lorus Therapeutics Enters Into A Research Agreement With Dr. Guido Marcucci 54 Lorus Therapeutics Enters Into An Agreement With Sumitomo and Koken 55 Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011 GMDHC1181CDB / Published MAY 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(3) Lorus Therapeutics Inc – Product Pipeline Review Licensing Agreements 56 Lorus Therapeutics Extends Agreement With Zor Pharmaceuticals 56 Lorus Therapeutics Enters Into Licensing Agreement With Zor Pharmaceuticals 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 59 Contact Us 59 Disclaimer
Pages to are hidden for
"Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011"Please download to view full document